(Elipovimab)Biosimilar Reference Antibody-GS40215

货号：GS40215

Elipovimab (development code GS-9722) is an investigational, broadly neutralizing monoclonal antibody (bNAb) developed for the prevention and treatment of HIV-1 infection. As part of a next-generation class of long-acting HIV therapeutics, it is engineered to directly target and neutralize a wide spectrum of circulating HIV-1 strains. Its primary mechanism is to bind to a highly conserved region on the surface of the HIV-1 envelope glycoprotein, thereby preventing the virus from attaching to and entering human host cells (CD4+ T cells), effectively blocking the initial step of infection.